- Home
- SER vs NSPR Comparison
SER vs NSPR Comparison
Compare SER & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SER
- NSPR
- Stock Information
- Founded
- SER 2017
- NSPR 2005
- Country
- SER United States
- NSPR Israel
- Employees
- SER N/A
- NSPR N/A
- Industry
- SER Biotechnology: Pharmaceutical Preparations
- NSPR Medical/Dental Instruments
- Sector
- SER Health Care
- NSPR Health Care
- Exchange
- SER Nasdaq
- NSPR Nasdaq
- Market Cap
- SER 54.3M
- NSPR 63.0M
- IPO Year
- SER 2018
- NSPR N/A
- Fundamental
- Price
- SER $5.17
- NSPR $2.45
- Analyst Decision
- SER
- NSPR Buy
- Analyst Count
- SER 0
- NSPR 1
- Target Price
- SER N/A
- NSPR $4.50
- AVG Volume (30 Days)
- SER 17.4K
- NSPR 36.4K
- Earning Date
- SER 11-12-2024
- NSPR 11-12-2024
- Dividend Yield
- SER N/A
- NSPR N/A
- EPS Growth
- SER N/A
- NSPR N/A
- EPS
- SER N/A
- NSPR N/A
- Revenue
- SER $3,156,637.00
- NSPR $6,821,000.00
- Revenue This Year
- SER N/A
- NSPR $12.28
- Revenue Next Year
- SER N/A
- NSPR $53.44
- P/E Ratio
- SER N/A
- NSPR N/A
- Revenue Growth
- SER 2436.14
- NSPR 24.70
- 52 Week Low
- SER $3.81
- NSPR $1.81
- 52 Week High
- SER $23.18
- NSPR $3.42
- Technical
- Relative Strength Index (RSI)
- SER 37.60
- NSPR 61.14
- Support Level
- SER $5.00
- NSPR $2.07
- Resistance Level
- SER $5.76
- NSPR $3.05
- Average True Range (ATR)
- SER 0.77
- NSPR 0.22
- MACD
- SER -0.14
- NSPR 0.03
- Stochastic Oscillator
- SER 34.39
- NSPR 63.92
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.